A variety of new biomarkers and gene signatures with prognostic significance for risk stratification for DLBCL also has been identified, such as cell of origin (19), C-MYC, BCL-2, or BCL-6 rearrangements (20), MYC/BCL2 expression (21), PD-1 and PD-L1 expression (22, 23), absolute lymphocyte/monocyte count (24–26), which have all shown promise as new predictive factors. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.